200µg versus 400µg sublingual misoprostol in prevention of postpartum haemorrhage

Not Applicable

• Conditions: Pregnancy and Childbirth; POSTPARTUM HAEMORRHAGE

• Registration Number: PACTR201505001107182
• Lead Sponsor: Dr I.A Ugwu

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-04-16
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 0

Inclusion Criteria

Women at term with singleton pregnancy in active phase labour, or
women undergoing induction of labour and with anticipated spontaneous vaginal delivery

Exclusion Criteria

contraindications for use of misoprostol such as asthma
paturients undergoing caesarean section
presence of coagulation disorders
pre-eclampsia and other hypertensive diseases in pregnancy
anaemia
conditions requiring prophylactic oxytocin infusion after delivery such as grandmultiparity, multiple pregnancy, polyhydramnios and coexisiting uterine fibroids
previous history of postpartum haemorrhage
history of anteparturm haemorrhage
Refusal or withdrawal of consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
amount of postpartum blood loss;presence of notable side effects of misoprostol;occurence of postpartum haemorrhage

Secondary Outcome Measures

Name	Time	Method
change in packed cell volume;need for blood transfusion